Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis

X
Trial Profile

Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tapinarof (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline; GSK
  • Most Recent Events

    • 16 Jun 2020 Secondary efficacy and patient-reported outcomes analyses published in the Dermavant Sciences Media Release.
    • 02 Jun 2020 Primary endpoint (Proportion of subjects who have a Investigator Global Assessment (IGA) score of clear (0) or almost clear (1) at Week 12 and a minimum 2-grade improvement in IGA score from Baseline to Week 12) has been met.
    • 02 Jun 2020 Results published in the Journal of the American Academy of Dermatology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top